Nobivac^® FeLV Questions and Answers

For active immunisation of healthy cats to prevent persistent feline leukaemia-virus viraemia and any associated clinical signs of feline leucosis.

The onset of protection begins 2 weeks after immunisation.

The duration of protection lasts one year after the primary vaccination course.

Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated.

Do not use in pregnant cats.

The use is not recommended during lactation.

Nobivac FeLV requires storage in a refrigerator between 2^oC and 8^oC. Do not freeze. Protect from sunlight.

There are no breed specific contraindications for Nobivac FeLV.

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with cat vaccines of the Nobivac range containing feline calicivirus (F9 strain), feline rhinotracheitis virus (G2620A strain) and/or feline panleucopenia virus (MW-1 or Bristol strain).

Do not mix with other medicinal products except cat vaccines of the Nobivac range containing feline calicivirus (F9 strain), feline rhinotracheitis virus (G2620A strain) and/or feline panleucopenia virus (MW-1 or Bristol strain).

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after another veterinary medicinal product therefore needs to be made on a case by case basis.

A first injection in cats from minimum 8 weeks of age.

A second injection of cats 3 to 4 weeks later.